“Whether or not atrial fibrillation (AF) is an independent predictor of outcome in heart failure (HF),” comment the EMPHASIS-HF investigators, “its occurrence is commonly associated with symptom deterioration ... Consequently, AF is best avoided, if possible.” A prospective analysis of EMPHASIS-HF has demonstrated that the mineralocorticoid-receptor antagonist eplerenone is associated with reduced incidence of new-onset AF in the setting of mild systolic HF.
The EMPHASIS-HF investigators assessed patients with mild systolic HF both with (n = 943) and without (n = 1,794) AF or atrial flutter (AFF) at baseline. In the patients without AFF, eplerenone was associated with a reduced rate of new-onset AF during follow-up (median 21 months; 2.7% vs 4.5%; HR 0.58, 95% CI 0.35–0.96, P = 0.034). A trend remained when the data was adjusted for covariates (HR 0.71, 95% CI 0.49–1.05, P = 0.087).
The effect of eplerenone on first occurrence of cardiovascular death or hospitalization for HF (the primary end point of EMPHASIS-HF) did not differ between patients with (HR 0.60, 95% CI 0.46–0.79) and without (HR 0.70, 95% CI 0.57–0.85) AFF at baseline (P for interaction = 0.411).
Few treatments are proven to prevent new-onset AF in patients with HF. Therefore, the news that eplerenone (added to recommended therapy) was associated with reduced incidence of new-onset AF in the patients assessed in EMPHASIS-HF is a welcome addition to the literature.
ORIGINAL RESEARCH PAPER
Swedberg, K. et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J. Am. Coll. Cardiol. 59, 1598–1603 (2012)
Rights and permissions
About this article
Cite this article
Mearns, B. EMPHASIS-HF links eplerenone with reduced risk of new-onset AF. Nat Rev Cardiol 9, 373 (2012). https://doi.org/10.1038/nrcardio.2012.68
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2012.68